Matchpoint Therapeutics closed a $150 million Series B to push its pipeline of oral covalent small molecules for autoimmune and inflammatory diseases. The financing supports advancement toward proof-of-concept and further development across the company’s programs targeting disease-relevant enzymes or pathways using oral dosing. The round underscores sustained investor focus on oral administration and covalent chemistry in immunology, where durability of target engagement and exposure profiles can be key differentiators. Matchpoint’s funding also suggests competitive pressure to demonstrate clinical feasibility and differentiation against a growing landscape of small-molecule immune modulators. For biotech teams, the scale of the round indicates that late preclinical-to-early clinical execution can still attract major capital when teams show a clear path to first-in-human and early biomarker strategies.